Beijing Ke Xing biological sinovac: Three big killer of pioneering work

Without SARS, people might not know Sinovac.　　This is the Beijing Branch Hing Biological Products Co., Ltd. General manager of the private entrepreneurs, in the national crisis, volunteered, in just 6 months, the rate of people to develop the "SARS virus inactivated vaccine."　　Some people can not help but ask, a small private enterprises, rely on what the responsibility of the country?　　Sinovac, or Beijing branch hing growth process, has its own killer ——— thick thin hair. From 1984 to isolate the first hepatitis A virus TZ84, to develop the first of the domestic hepatitis A enzyme-linked immune diagnostic reagents, from the 1999 first HAV inactivated vaccine successfully developed, to 2002 the vaccine listing, each step is in the accumulation of vitality, ready to send.　　Until the SARS hit, Sinovac blockbuster.　　At the moment, with the reporter joke past sinovac already "on the list", once the emergence of new infectious disease, he and his company will immediately armored battle.　　Killer one: A recruit fresh, eat the day Sinovac never thought of as "developed" like today. Tracing the source, from the hands to collect stool samples, to study the origin of hepatitis A, this is entirely from the doctor's conscience, and motivation from reality. In China at that time, hepatitis A was spread like a ghost in the world, and the patient was tortured. "There was no vaccine to prevent, and I had an urge to develop a vaccine," he said. "1984, he successfully isolated the first hepatitis A virus TZ84," This is the future of the "vaccine cause" buried a seed.　　1986, with the support of 80,000 Yuan Research Fund of Tangshan Science and Technology Commission, Sinovac and Partners developed the first hepatitis A diagnostic reagent. "In fact, it takes courage to get a vaccine," he said. "Generally speaking, from the discovery of pathogens to the discovery of pathological mechanisms, and then to the fight against the original, induced antibodies, to the final production of vaccines, the whole process will take 10 years; In addition, vaccines are a special product for healthy persons, with very stringent safety and efficacy requirements; More importantly, abroad,　　An investment in a vaccine research cycle usually requires 51 billion of dollars. Sinovac hands of limited funds, diagnostic reagents are not sales, the grand plan to make vaccines can only be stranded. During this period, he also tried to get AIDS diagnostic reagents, hepatitis C diagnostic reagents, but failed to end.　　He realized that he had a rare liver pathogen in his hand and that the hepatitis A vaccine was the way to go. However, what really prompted him to speed up the research process was a public health incident in 1988 ——— the outbreak of hepatitis A in Shanghai, the spring because of the consumption of contaminated subcrenata, and lack of effective vaccine intervention, about more than 300,000 people sick, hospital overcrowding, resulting in large areas of shutdown, closure, suspension,　　Become a shocking event in the history of modern infectious diseases. Sinovac sat still, vowing to get the inactivated vaccine out.　　1993, Sinovac with technology shares, with foreign cooperation set up Tangshan Yi Ann Bioengineering Co., Ltd., began to accumulate technology and talent for the research and development of hepatitis A vaccine. 1In 999 years, the inactivated hepatitis A vaccine was successfully developed. At this time Sinovac feel that they can do something for the country.　　In 2001, he cooperated with the unnamed group of Peking University to set up Beijing Branch Hing Biological Products Co., Ltd., the 2002 hepatitis A inactivated vaccine successfully listed, so that China's hepatitis A inactivated vaccine all rely on imports of the situation become history. Some envy Sinovac occupy the good and wrong, but in his opinion, the reason for the capital flow to him, is because of the seemingly small but extremely precious TZ84 virus strains. This is the so-called "master the core technology, it mastered the initiative of competition." "Innovation to eat is" a recruit fresh. But a single product of the hepatitis A vaccine does not accomplish the mission of providing vaccines for human disease. So Beijing Branch Hing will focus on the hepatitis A combined vaccine and flu vaccine development. [Page] Killer two: One step risk, the World Wide 2003, SARS outbreak. Sinovac soberly recognized that the state and people are facing a disaster, their own as the expert in the field of vaccines, should immediately stand up for the country, for the people problem-solving.　　With the strong support of the Ministry of Science and Technology, he began to unite all forces to develop the SARS vaccine.　　Beijing Branch Xing chooses "follow up", actually, it was a step away ——— they suspended the production application of hepatitis A combined vaccine and the clinical study of the influenza split vaccine, carrying out the financial pressure of the previous year's loss, relying solely on the sale of hepatitis A inactivated vaccine, insisting on the research of the inactivated vaccine against SARS. As the only private enterprise in the project team, Beijing Branch Xing has been playing an important role in the experience of vaccine research accumulated over the years. "We have a very good inactivated vaccine production platform, including cell culture, virus inactivation, purification, quality verification, and so on, we take this platform to provide support for SARS vaccine research." December 5, 2004, the world's first to report SARS cases in China, is of great significance ——— from Beijing Branch Hing independently developed Ⅰ phase of SARS vaccine clinical research unveiled.　　This indicates that China has made significant periodic achievements in controlling the SARS epidemic and ensuring people's health, while the project is less than 18 months away. The study of SARS vaccine, from the decision, application, approval to the final completion, Beijing Branch Hing to explore a response to the outbreak of new infectious disease vaccine emergency research and development of the road ——— to mobilize their own technology and talent reserves, to seek national policy support, integration of resources to work together.　　This provides a successful case for the realization of the national Science and Technology Development strategy goal of the enterprise as the subject of scientific and technological innovation.　　But when the SARS epidemic was completely gone, the vaccine was sealed off and all the inputs were lost. Some people say, this is not a white busy? Sinovac said to reporters: "From a commercial point of view, the development of SARS vaccine is a failure case, because the enterprise finally did not profit." But vaccines are a special product that cannot be measured by economic indicators. When the public face the threat of life security, must be socially responsible scientists, entrepreneurs and the government stand together.　　”In January 2004, there were cases of human infection of avian influenza in South-East Asia. Sinovac predicts that avian flu is likely to become an influenza pandemic that threatens human security. So, in China has not yet occurred in the case of human infection, he once again active, timely launch of human avian influenza vaccine research, vowed to "risk chess" a go to the end. [Page] Killer three: A flag, a half Bishan clinical research results of avian influenza vaccine Ⅰ in the world's most authoritative medical journal, The Lancet, September 7, 2006, marks a global recognition of the results of the Chinese bird flu vaccine study.　　Beijing Branch Hing once again proved ——— in the face of major global public emergencies, China is at the forefront of the world. By the end of June 2007, Beijing Branch Hing's hepatitis A inactivated vaccine in the domestic sales of more than 8.4 million, in the hepatitis A inactivated vaccine in the domestic market share ranked first, for China's 1.3 billion people, especially about 16 million newborns each year to provide a truly safe, efficient, non-polluting, With the international advanced level of hepatitis A prevention products.　　The company is working to develop overseas markets and is actively involved in the World Health Organization's efforts to improve epidemiological prevention in developing countries. Beijing Branch Xing to "let Chinese children use international quality vaccines, let the world children use the vaccine produced in China" as the goal, it is under the call of the banner, Beijing Branch Hing gathered a large number of high-quality vaccine research and development personnel and management personnel, formed an excellent sales team, the use of advanced technology to develop new vaccines,　　And the traditional vaccine technical renovation, the final achievement of the Beijing branch Hing half, but also greatly enhance the Chinese people's self-confidence. Today, Beijing Branch Hing has grown into a reputable vaccine research and development and production enterprises at home and abroad, with the internationalization of product development and product quality internationalization, it takes a high-spirited attitude to the international arena, with a number of international agencies to establish and maintain good exchanges and cooperative relations.　　Beijing Branch, which has been listed on the US stock exchange for nearly three years and has a market value of $110 million, is participating in a more spectacular global competition with the international vaccine giants in the same markets and rules. "To put the country's needs and public demand first, innovation is the driving force." "The adventurous Sinovac smiled and said goodbye to the journalist," of course, the risk is built on the accumulated self-confidence. ”